Recombinant Humanised Anti-PD-1 Monoclonal Antibody Injection
Phase 2 Clinical Trial
HLX10. Recombinant Humanised Anti-PD-1 Monoclonal Antibody
Injection independently researched and developed by Henlius, is for the treatment of
various solid tumours and can be applied in combination with other products for
immuno-oncology therapy. Currently, HLX10 is also further developed for the treatment of chronic hepatitis b infection. HLX10 was approved to enter into clinical trials in
the US, Taiwan China and Mainland China. Moreover, HLX10 plus HLX04 combination therapy has received Investigational New Drug (IND) approval from the NMPA and has entered
into phase 2 clinical trial in China. HLX10 plus HLX07 combination therapy is under IND review.
Recently, the first patient was dosed in a phase 2 clinical study of HLX10 as mono-therapy in patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors who failed to respond to standard therapy.